Results 31 to 40 of about 40,707 (134)

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

ESMO Open, 2020
On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with ...
Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Nikolaos Zafiropoulos, Sahra Ali, Paula van Hennik, Christian Syvertsen, Bjorn Oddvar Strøm, Mats Ökvist, Brigitte Keller-Stanislawski, Elias Pean, Silvy da Rocha Dias, Franscesco Pignatti   +12 more
doaj   +1 more source

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Frontiers in Pharmacology, 2021
Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov ...
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan   +9 more
doaj   +1 more source

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2020
Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically.
Caroline Robert, Christine Mateus, Christophe Massard, Roger Sun, Eric Deutsch, Lydie Cassard, Rastilav Bahleda, Severine Roy, Emilie Routier, Nathalie Chaput-Gras, Caroline Caramella, Emilie Lanoy, Alicia Larive, Yun Gan Tao, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, J -C Soria   +17 more
doaj   +1 more source

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab [PDF]

Journal of Immunotherapy and Precision Oncology, 2018
Ipilimumab and nivolumab are human monoclonal antibodies used in cancer therapy. Ipilimumab targets cytotoxic T-lymphocyte-associated antigen and nivolumab acts against programmed death receptor-1. Both drugs have extensive side effect profiles with high
Shelby L Kubicki, Macartney E Welborn, Anisha B Patel   +2 more
doaj   +1 more source

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

Melanoma Management, 2018
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns, Jill A Bell, Aaron Galaznik, Stefanie M Puglielli, Allie B Cichewicz, Talia Boulanger, Ignacio Garcia-Ribas   +6 more
doaj   +1 more source

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study

Frontiers in Oncology, 2020
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology.
Muhammad A. Khattak, Muhammad A. Khattak, Muhammad A. Khattak, Afaf Abed, Afaf Abed, Anna L. Reid, Ashleigh C. McEvoy, Michael Millward, Michael Millward, Melanie Ziman, Elin S. Gray   +10 more
doaj   +1 more source

Ipilimumab-Induced Neutropenia in Melanoma

Journal of Investigative Medicine High Impact Case Reports, 2016
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related.
Makiko Ban-Hoefen MD, Richard Burack MD, Lynn Sievert NP, Deepak Sahasrabudhe MD   +3 more
doaj   +1 more source

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. [PDF]

PLoS ONE, 2018
Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized that CTLA-4 blockade may enhance immune response to HIV-1 and result in better control of ...
Elizabeth Colston, Dennis Grasela, David Gardiner, R Pat Bucy, Blisse Vakkalagadda, Alan J Korman, Israel Lowy   +6 more
doaj   +1 more source

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Journal of Translational Medicine, 2012
Background Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ...
Wang Wenshi, Yu Daohai, Sarnaik Amod A, Yu Bin, Hall Maclean, Morelli Dawn, Zhang Yonghong, Zhao Xiuhua, Weber Jeffrey S   +8 more
doaj   +1 more source

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Diagnostics, 2018
Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone.
Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis   +4 more
doaj   +1 more source